Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Abstract
CARTITUDE-1 evaluated ciltacabtagene autoleucel (cilta-cel) in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM). We describe overall survival (OS), ≥5-year progression-free outcomes, associated biomarkers, and safety, with a median study follow-up of 61.3 months. For the 97 treated patients, median OS was 60.7 months (95% CI, 41.9 to not estimable). One third (32/97) of patients remain alive and progression-free for ≥5 years after a single cilta-cel infusion, without maintenance treatment. Twelve of these patients treated at a single center underwent serial minimal residual disease (MRD) and positron emission tomography-computed tomography assessments, and all (100%) were MRD-negative (at least 10 −5 threshold) and imaging-negative at year 5 or later after cilta-cel. Baseline characteristics, including the presence of high-risk cytogenetics and extramedullary disease, were generally comparable for the 32 patients who were progression-free for ≥5 years versus patients who had progressive disease by year 5. A trend of lower baseline tumor burden, higher fraction of naïve T-cells in the cilta-cel drug product, higher T cell-to-neutrophil ratio, higher hemoglobin and platelets at baseline, and higher effector-to-target ratio were associated with ≥5-year progression-free status. The safety profile of cilta-cel remained consistent with previous reports. To our knowledge, our data provide the first evidence that cilta-cel is potentially curative in patients with RRMM.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (33)
Sundar Jagannath
Icahn School of Medicine at Mount Sinai, New York
Thomas G. Martin
Yi Lin
Adam D. Cohen
Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Noopur Raje
1Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
Myo Htut
City of Hope, Duarte, California, United States
Abhinav Deol
Wayne State University, Detroit, Michigan, United States
Mounzer Agha
21University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, United States
Jesus G. Berdeja
Tennessee Oncology, Nashville, TN
Alexander M. Lesokhin
Memorial Sloan Kettering Cancer Center
Jessica J. Liegel
Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA
Adriana Rossi
1Icahn School of Medicine at Mount Sinai, New York, United States
Alex Lieberman-Cribbin
12Icahn School of Medicine at Mount Sinai, New York, United States
Saad Z. Usmani
Memorial Sloan Kettering Cancer Center, New York
Binod Dhakal
2Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
Samir Parekh
Icahn School of Medicine at Mount Sinai, New York
Hui Li
Feng Wang
Rocio Montes De Oca
5Johnson & Johnson, Oncology Translational Research, Spring House, United States
Vicki Plaks
Johnson & Johnson, Spring House, PA
Huabin Sun
Arnob Banerjee
Johnson & Johnson, Spring House, PA
Jordan M. Schecter
Johnson & Johnson, Raritan, NJ
Nikoletta Lendvai
Johnson & Johnson, Raritan, NJ
Deepu Madduri
8Johnson & Johnson, Raritan, United States
Tamar Lengil
Johnson & Johnson, Raritan, NJ
Jieqing Zhu
1Versiti Blood Research Institute, Versiti Blood Center of Wisconsin, Milwaukee, WI
Mythili Koneru
17Legend Biotech USA Inc., Somerset, United States
Muhammad Akram
Legend Biotech USA Inc, Somerset, NJ
Nitin Patel
Legend Biotech USA, Somerset, NJ
Octavio Costa Filho
Legend Biotech USA Inc, Somerset, NJ
Andrzej J. Jakubowiak
University of Chicago Medical Center, Chicago, IL
Peter M. Voorhees
Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC